415 related articles for article (PubMed ID: 32985963)
21. Why Oxford's positive COVID vaccine results are puzzling scientists.
Callaway E
Nature; 2020 Dec; 588(7836):16-18. PubMed ID: 33230278
[No Abstract] [Full Text] [Related]
22. Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.
Das BK; Chakraborty D
J Phys Chem Lett; 2020 Nov; 11(22):9920-9930. PubMed ID: 33174418
[TBL] [Abstract][Full Text] [Related]
23. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
25. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies.
Rele S
Hum Vaccin Immunother; 2021 Apr; 17(4):1122-1127. PubMed ID: 32993453
[TBL] [Abstract][Full Text] [Related]
27. New Chinese vaccine could bolster global arsenal.
Cohen J
Science; 2021 Oct; 374(6563):12-13. PubMed ID: 34591635
[No Abstract] [Full Text] [Related]
28. Promise and challenges in the development of COVID-19 vaccines.
Chen W
Hum Vaccin Immunother; 2020 Nov; 16(11):2604-2608. PubMed ID: 32703069
[TBL] [Abstract][Full Text] [Related]
29. A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein.
Roy S; Ghani K; de Campos-Lima PO; Caruso M
Virus Res; 2021 Apr; 295():198305. PubMed ID: 33482242
[TBL] [Abstract][Full Text] [Related]
30. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
[TBL] [Abstract][Full Text] [Related]
31. Efforts towards a COVID-19 vaccine.
Brüssow H
Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
[TBL] [Abstract][Full Text] [Related]
32. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.
Bai Z; Cao Y; Liu W; Li J
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200602
[TBL] [Abstract][Full Text] [Related]
33. In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.
Can H; Köseoğlu AE; Erkunt Alak S; Güvendi M; Döşkaya M; Karakavuk M; Gürüz AY; Ün C
Sci Rep; 2020 Dec; 10(1):22387. PubMed ID: 33372181
[TBL] [Abstract][Full Text] [Related]
34. Iran hopes to defeat COVID with home-grown crop of vaccines.
Mallapaty S
Nature; 2021 Aug; 596(7873):475. PubMed ID: 34404947
[No Abstract] [Full Text] [Related]
35. Research progress and challenges to coronavirus vaccine development.
Zhou P; Li Z; Xie L; An D; Fan Y; Wang X; Li Y; Liu X; Wu J; Li G; Li Q
J Med Virol; 2021 Feb; 93(2):741-754. PubMed ID: 32936465
[TBL] [Abstract][Full Text] [Related]
36. Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.
Liu Q; Ding Z; Lan J; Wong G
Methods Mol Biol; 2022; 2410():193-208. PubMed ID: 34914048
[TBL] [Abstract][Full Text] [Related]
37. Recombinant vaccines for COVID-19.
Yadav T; Srivastava N; Mishra G; Dhama K; Kumar S; Puri B; Saxena SK
Hum Vaccin Immunother; 2020 Dec; 16(12):2905-2912. PubMed ID: 33232211
[TBL] [Abstract][Full Text] [Related]
38. Vaccinemakers ponder how to adapt to virus variants.
Kupferschmidt K
Science; 2021 Jan; 371(6528):448-449. PubMed ID: 33510004
[No Abstract] [Full Text] [Related]
39. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.
Baj A; Novazzi F; Genoni A; Ferrante FD; Taborelli S; Pini B; Partenope M; Valli M; Gasperina DD; Capuano R; Prestia M; Spezia PG; Azzi L; Focosi D; Maggi F
Emerg Microbes Infect; 2021 Dec; 10(1):1254-1256. PubMed ID: 34110974
[TBL] [Abstract][Full Text] [Related]
40. Genetic Variants of SARS-CoV-2-What Do They Mean?
Lauring AS; Hodcroft EB
JAMA; 2021 Feb; 325(6):529-531. PubMed ID: 33404586
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
